Eric Nadler

4.8k total citations
49 papers, 1.3k citations indexed

About

Eric Nadler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Eric Nadler has authored 49 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 12 papers in Economics and Econometrics. Recurrent topics in Eric Nadler's work include Lung Cancer Treatments and Mutations (19 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and Economic and Financial Impacts of Cancer (11 papers). Eric Nadler is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and Economic and Financial Impacts of Cancer (11 papers). Eric Nadler collaborates with scholars based in United States, United Kingdom and Canada. Eric Nadler's co-authors include Peter J. Neumann, Peter A. Ubel, Katherine Treiman, Douglas J. Rupert, Richard L. Street, Lauren McCormack, Pamela Williams-Piehota, William Lawrence, Neeraj K. Arora and James M. Woodruff and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Journal of Bone and Joint Surgery.

In The Last Decade

Eric Nadler

47 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric Nadler United States	17	507	497	329	323	189	49	1.3k
Amy N. Luckenbaugh United States	17	242 0.5×	669 1.3×	192 0.6×	222 0.7×	240 1.3×	66	1.8k
Alexander P. Cole United States	26	647 1.3×	792 1.6×	395 1.2×	297 0.9×	198 1.0×	154	2.3k
Timothy J. Daskivich United States	26	499 1.0×	961 1.9×	204 0.6×	274 0.8×	194 1.0×	97	2.0k
Rupal Ramani United States	10	751 1.5×	412 0.8×	294 0.9×	66 0.2×	317 1.7×	16	1.8k
Alison T. Brenner United States	23	1.1k 2.3×	847 1.7×	209 0.6×	570 1.8×	227 1.2×	69	2.1k
Roxanne Cosby Canada	17	334 0.7×	269 0.5×	133 0.4×	268 0.8×	205 1.1×	32	1.3k
Shirley M. Bluethmann United States	15	1.0k 2.0×	384 0.8×	95 0.3×	323 1.0×	273 1.4×	33	2.1k
Lauren P. Wallner United States	28	656 1.3×	430 0.9×	232 0.7×	300 0.9×	225 1.2×	130	2.0k
Beatriz Korc‐Grodzicki United States	21	371 0.7×	244 0.5×	155 0.5×	91 0.3×	194 1.0×	78	1.5k
Manali I. Patel United States	25	1.0k 2.0×	400 0.8×	322 1.0×	310 1.0×	742 3.9×	140	2.0k

Countries citing papers authored by Eric Nadler

Since Specialization

Citations

This map shows the geographic impact of Eric Nadler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Nadler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Nadler more than expected).

Fields of papers citing papers by Eric Nadler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Nadler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Nadler. The network helps show where Eric Nadler may publish in the future.

Co-authorship network of co-authors of Eric Nadler

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Nadler. A scholar is included among the top collaborators of Eric Nadler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Nadler. Eric Nadler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Skoulidis, Ferdinandos, Ticiana Leal, Stephen V. Liu, et al.. (2025). Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1 , or KRAS : the TRITON study. Therapeutic Advances in Medical Oncology. 17. 22831347–22831347.

Leal, Ticiana, Eric Nadler, Sandip Pravin Patel, et al.. (2024). P4.11D.01 TRITON: Tremelimumab + Durvalumab + Chemotherapy (CT) vs Pembrolizumab + CT in mNSCLC with STK11, KEAP1 and/or KRAS Mutations. Journal of Thoracic Oncology. 19(10). S389–S389.

Black, Christopher M., Eric Nadler, John Murphy, et al.. (2023). Real-world study of patients with locally advanced HNSCC in the community oncology setting. Frontiers in Oncology. 13. 1155893–1155893. 3 indexed citations

Nadler, Eric, Anupama Vasudevan, Yunfei Wang, & Sarika Ogale. (2022). Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network. SHILAP Revista de lepidopterología. 31. 100522–100522. 17 indexed citations

Nadler, Eric, et al.. (2020). Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. Advances in Therapy. 37(2). 946–954. 18 indexed citations

Nadler, Eric, Kathleen M. Aguilar, Marley Boyd, et al.. (2020). Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices. Sarcoma. 2020. 1–9. 2 indexed citations

Nadler, Eric, Bhakti Arondekar, Kathleen M. Aguilar, et al.. (2020). Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study. Journal of Cancer Research and Clinical Oncology. 147(3). 671–690. 31 indexed citations

Nadler, Eric, et al.. (2018). MA08.06 Outcomes Among Patients with EGFR-Mutant Metastatic NSCLC with and without Brain Metastases. Journal of Thoracic Oncology. 13(10). S383–S383. 1 indexed citations

Aguilar, Kathleen M., Katherine B. Winfree, Catherine E. Muehlenbein, et al.. (2018). Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis. Advances in Therapy. 35(11). 1905–1919. 11 indexed citations

10.

Nadler, Eric, et al.. (2018). Treatment Patterns and Clinical Outcomes Among Metastatic Non–Small-Cell Lung Cancer Patients Treated in the Community Practice Setting. Clinical Lung Cancer. 19(4). 360–370. 38 indexed citations

11.

Fallowfield, Lesley, Eric Nadler, I. Gilloteau, et al.. (2017). Quality of survival: a new concept framework to assess the quality of prolonged life in cancer. Sussex Research Online (University of Sussex). 2(4). 225–232. 9 indexed citations

12.

Ersek, Jennifer L., et al.. (2017). Clinical Pathways and the Patient Perspective in the Pursuit of Value-Based Oncology Care. American Society of Clinical Oncology Educational Book. 37. 597–606. 4 indexed citations

13.

Lin, Pei‐Jung, Thomas W. Concannon, Dan Greenberg, et al.. (2013). Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents. Expert Review of Pharmacoeconomics & Outcomes Research. 13(4). 513–522. 14 indexed citations

14.

Ubel, Peter A., Scott R. Berry, Eric Nadler, et al.. (2012). In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival. Health Affairs. 31(4). 709–717. 22 indexed citations

15.

McCormack, Lauren, Katherine Treiman, Douglas J. Rupert, et al.. (2011). Measuring patient-centered communication in cancer care: A literature review and the development of a systematic approach. Social Science & Medicine. 72(7). 1085–1095. 276 indexed citations

16.

Nadler, Eric, et al.. (2011). Costs and Clinical Outcomes among Patients with Second-Line Non-small Cell Lung Cancer in the Outpatient Community Setting. Journal of Thoracic Oncology. 7(1). 212–218. 12 indexed citations

17.

Rosenberger, Patricia H., Jeannette R. Ickovics, Elissa S. Epel, et al.. (2009). Surgical Stress-Induced Immune Cell Redistribution Profiles Predict Short-Term and Long-Term Postsurgical Recovery. Journal of Bone and Joint Surgery. 91(12). 2783–2794. 56 indexed citations

18.

Chu, Edward, et al.. (2005). Current Data with HMG-CoA Reductase Inhibitors (Statins) for Colorectal Cancer Prevention. Clinical Colorectal Cancer. 5(4). 245–246. 3 indexed citations

19.

Solomon, Daniel H., Jonathan L. Schaffer, Jeffrey N. Katz, et al.. (2000). Can History and Physical Examination Be Used as Markers of Quality?. Medical Care. 38(4). 383–391. 33 indexed citations

20.

Nadler, Eric, et al.. (1999). Does a year make a difference? changes in physician satisfaction and perception in an increasingly capitated environment. The American Journal of Medicine. 107(1). 38–44. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact